

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: November 5, 2004, 13:50:17 ; Search time 74.3927 seconds
(without alignments)
3081.324 Million cell updates/sec

Title: US-09-937-636-4

Perfect score: 3377
Sequence: 1 MLLPILLSLLGSGQAMGR.....RPEARNPKGTQADYAEVKFQ 639

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2002273 seqs, 358729299 residues

Total number of hits satisfying chosen parameters: 2002273

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A Genesepc 23Sep04: *
1: Genesepc1980s: *
2: Genesepc1990s: *
3: Genesepc2000s: *
4: Genesepc2001s: *
5: Genesepc2002s: *
6: Genesepc2003as: *
7: Genesepc2003bs: *
8: Genesepc2004s: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	3377	100.0	639	AAW81023	Human sia
2	3377	100.0	639	AAW81023	Human obo
3	3354	99.3	639	AAW81023	Human obo
4	3354	99.3	639	AAW81023	Human nov
5	3354	99.3	639	AAW81023	Human nov
6	3338	98.8	639	AAW81023	Human nov
7	3334	98.7	639	AAW81023	Human nov
8	3334	98.7	639	AAW81023	Human nov
9	3334	98.7	639	AAW81023	Human nov
10	3334	98.7	639	AAW81023	Human nov
11	3299	97.7	639	AAW81023	Human nov
12	3174.5	94.0	710	AAW81023	Human nov
13	2903.5	82.6	544	AAW81023	Human nov
14	2903.5	82.6	544	AAW81023	Human nov
15	2903.5	82.6	544	AAW81023	Human nov
16	2903.5	82.6	544	AAW81023	Human nov
17	2903.5	82.6	544	AAW81023	Human nov
18	2903.5	82.6	544	AAW81023	Human nov
19	2903.5	82.6	544	AAW81023	Human nov
20	2903.5	82.6	544	AAW81023	Human nov
21	2903.5	82.6	544	AAW81023	Human nov
22	2903.5	82.6	544	AAW81023	Human nov
23	2903.5	82.6	544	AAW81023	Human nov
24	2903.5	82.6	544	AAW81023	Human nov
25	2903.5	82.6	544	AAW81023	Human nov

26	2790.5	82.6	544	6	ABU96187	Novel hum
27	2790.5	82.6	544	6	ABU92618	Human sec
28	2790.5	82.6	544	6	ABO08695	Human sec
29	2790.5	82.6	544	6	ABO02747	Human sec
30	2790.5	82.6	544	6	ABR74901	Human sec
31	2790.5	82.6	544	6	ABR94663	Human sec
32	2790.5	82.6	544	6	ABO25226	Novel hum
33	2790.5	82.6	544	6	ABU85636	Human PRO
34	2790.5	82.6	544	6	ABU98796	Novel hum
35	2790.5	82.6	544	6	ABU98011	Novel hum
36	2790.5	82.6	544	6	ABU91717	Novel hum
37	2790.5	82.6	544	6	ABU72232	Novel hum
38	2790.5	82.6	544	6	ABU9410	Human PRO
39	2790.5	82.6	544	6	ABU8251	Human sec
40	2790.5	82.6	544	6	ABU67464	Human sec
41	2790.5	82.6	544	6	ABU80492	Human PRO
42	2790.5	82.6	544	6	ABR99410	Human sec
43	2790.5	82.6	544	6	ABR98800	Human sec
44	2790.5	82.6	544	6	ABO16323	Human sec
45	2790.5	82.6	544	6	ABR92223	Human sec

ALIGNMENTS

RESULT 1
AAW81023
ID AAW81023 standard; protein; 639 AA.
XX
AC AAW81023;
XX
DT 26-APR-1999 (first entry)
XX
DE Human sialoadhesin family 4 (SAP-1) polypeptide.
XX

SAP-4; sialoadhesin family; human; therapy; diagnosis; cancer;
inflammation; autoimmune disease; allergy; asthma; inflammation;
cerebellar degeneration; Alzheimer's disease; Parkinson's disease;
multiple sclerosis; amyotrophic lateral sclerosis; head injury;
septic shock; sepsis; stroke; osteoporosis; osteoarthritis;
ischemia reperfusion injury; cardiovascular disease; kidney disease;
liver disease; myocardial infarction; hypertension; hypotension; AIDS;
myelodysplastic syndrome; aplastic anaemia; baldness; infection.

Homo sapiens.

WO9853840-A1.

03-DEC-1998.

27-MAY-1998; 98WO-US010791.

27-MAY-1997; 97US-0047572P.

(SMIK) SMITHKLINE BEECHAM CORP.

Kikly KK, Erickson-Miller CL;

WPI; 1999-080779/07.

N-PSDB; AAV99911.

New sialoadhesin family 4 polypeptides and polynucleotides - useful to treat various diseases associated with SAP-4 expression.

Claim 1; Page 31; 48pp; English.

This is the amino acid sequence of new human sialoadhesin family 4 (SAP-4), as deduced from the nucleotide sequence of an isolated cDNA clone (see AAV99911). SAP-4 polynucleotides and polypeptides, and methods for producing such polypeptides in transformed host cells using recombinant techniques are disclosed. SAP-4, its agonists and antagonists, and nucleic acid molecules that enhance or inhibit SAP-4 expression, may be used to treat patients in need of enhancement or inhibition of SAP-4

expression or activity. Conditions that may benefit from such treatment include cancer, inflammation, autoimmunity, allergy, asthma, rheumatoid arthritis, CNS inflammation, cerebellar degeneration, Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, head injury damage and other neurological disorders, septic shock, sepsis, stroke, osteoporosis, osteoarthritis, ischemia reperfusion injury, cardiovascular disease, kidney disease, liver disease, ischemic injury, myocardial infarction, hypotension, hypertension, AIDS, myelodysplastic syndromes and other haematologic abnormalities, aplastic anaemia, male baldness pattern and bacterial, protozoal, fungal and viral infections related to SAP-4 polypeptide activity. Methods of identifying agonists/antagonists/inhibitors are also provided, as well as diagnostic assays for detecting diseases associated with inappropriate SAP-4 activity or levels

XX
XX
SQ

Query Match 100.0%; Score 3377; DB 2; Length 639;
Best Local Similarity 100.0%; Pred. No. 2.3e-232; Indels 0; Gaps 0;
Matches 639; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MLLPILLSLLGGSSQAMGDFWIRVQESVMVPEGLCISVPCSFYPRQDMGTSTPAYGYW 60
Db 1 MLLPILLSLLGGSSQAMGDFWIRVQESVMVPEGLCISVPCSFYPRQDMGTSTPAYGYW 60
Qy 61 FKAVTTTKGAPVATNHQSRVEVSTGRFOLTGDPKAGNCSLVIRDAQMDQESQYFFRV 120
Db 61 FKAVTTTKGAPVATNHQSRVEVSTGRFOLTGDPKAGNCSLVIRDAQMDQESQYFFRV 120
Qy 121 ERGSVRYNFMNDGFFLKVTLSFTPRPDQDHTDLTCHVDSRKGVSQAQRTVRLVAYAP 180
Db 121 ERGSVRYNFMNDGFFLKVTLSFTPRPDQDHTDLTCHVDSRKGVSQAQRTVRLVAYAP 180
Qy 181 RDLVTSISRDNTPALEPQGNVPLYEAQKQFLLCDAADSPATLSWLNQVLS 240
Db 181 RDLVTSISRDNTPALEPQGNVPLYEAQKQFLLCDAADSPATLSWLNQVLS 240
Qy 241 HPWGPRLGLELPVKGAGDSGRYTCRAENRLGSGQORALDLSVQYPPENLRVWVSQANRTV 300
Db 241 HPWGPRLGLELPVKGAGDSGRYTCRAENRLGSGQORALDLSVQYPPENLRVWVSQANRTV 300
Qy 301 LENLNGTSLPVLGQSLCLVCVTHSSPPARLSWTORQGVLSPPQSDPGVLELPRVQVE 360
Db 301 LENLNGTSLPVLGQSLCLVCVTHSSPPARLSWTORQGVLSPPQSDPGVLELPRVQVE 360
Qy 361 HEGEFTCHARHPLGSHVSLSVHYSPKLLGPGSCSWEAEGHLCSSQASPAFLSLANWL 420
Db 361 HEGEFTCHARHPLGSHVSLSVHYSPKLLGPGSCSWEAEGHLCSSQASPAFLSLANWL 420
Qy 421 GEEILLEGNSQDSFEVTPSSAGPWANSSLSLHGGLSSGLRLCRANVHGAQSGSILQLP 480
Db 421 GEEILLEGNSQDSFEVTPSSAGPWANSSLSLHGGLSSGLRLCRANVHGAQSGSILQLP 480
Qy 481 DKKGLISTAFSNGAFGLGITALLFLCLALIMKILPKRPTOTETPRPSRHSHTILDYI 540
Db 481 DKKGLISTAFSNGAFGLGITALLFLCLALIMKILPKRPTOTETPRPSRHSHTILDYI 540
Qy 541 NVVPTAGLAQRNKAQTPNSPRTPLPGAPSPESKKNQKQYQLPSPFKSSTQAPES 600
Db 541 NVVPTAGLAQRNKAQTPNSPRTPLPGAPSPESKKNQKQYQLPSPFKSSTQAPES 600
Qy 601 QESCEELHYATLNPFGVPRPREARWPKGTQADYAEVKFO 639
Db 601 QESCEELHYATLNPFGVPRPREARWPKGTQADYAEVKFO 639

RESULT 2
AAV97543
ID AAV97543 standard; protein; 639 AA.
XX
XX
AC AAV97543;
XX
XX 12-FEB-2001 (first entry)

XX
DB
XX
XX
XX
XX
XX
OS
XX
PN
XX
PD
XX
PF
XX
PR
XX
PA
XX
PI
XX
DR
XX
XX
PT
PT
PT
XX
PS
XX
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
CC
SQ

Human obesity protein binding protein-2 homologue #2.
Human obesity protein binding protein-2 homologue; hOB-BP2h; obesity;
obesity-related disorder; therapy.
Homo sapiens.
W0200059942-A2.
12-OCT-2000.
22-MAR-2000; 2000MO-US006682.
02-APR-1999; 99US-0127667P.
(ELIL) LILLY & CO ELI.
Su EW, Wei J;
WPI; 2000-664992/64.
N-PSDB; AAA37848.
New human obesity protein binding protein-2 homologue nucleic acids,
polynucleotides and polypeptides useful for producing medicament for
treating obesity and/or obesity-related disorders.
Claim 9; Page 89-91; 92pp; English.
This sequence is a human obesity protein binding protein-2 homologue (hOB
-BP2h) of the invention. The hOB-BP2h nucleic acids and polypeptides may
be used for the manufacture of a medicament for the treatment of obesity
and/or obesity-related disorders. The hOB-BP2h nucleic acids are useful
as probes or amplification primers in the detection, quantification or
isolation of gene sequences or transcripts, for recombinant expression of
hOB-BP2h polypeptides, as immunogens in the preparation and screening of
antibodies, and in sense or antisense suppression of one or more hOB-BP2h
genes or nucleic acids, host cell or tissue in vivo or in vitro.
Antigenic epitope-bearing peptides and polypeptides are useful for
raising or screening antibodies that specifically binds to the hOB-BP2h
polypeptides

Sequence 639 AA;

Query Match 100.0%; Score 3377; DB 3; Length 639;
Best Local Similarity 100.0%; Pred. No. 2.3e-232; Indels 0; Gaps 0;
Matches 639; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MLLPILLSLLGGSSQAMGDFWIRVQESVMVPEGLCISVPCSFYPRQDMGTSTPAYGYW 60
Db 1 MLLPILLSLLGGSSQAMGDFWIRVQESVMVPEGLCISVPCSFYPRQDMGTSTPAYGYW 60
Qy 61 FKAVTTTKGAPVATNHQSRVEVSTGRFOLTGDPKAGNCSLVIRDAQMDQESQYFFRV 120
Db 61 FKAVTTTKGAPVATNHQSRVEVSTGRFOLTGDPKAGNCSLVIRDAQMDQESQYFFRV 120
Qy 121 ERGSVRYNFMNDGFFLKVTLSFTPRPDQDHTDLTCHVDSRKGVSQAQRTVRLVAYAP 180
Db 121 ERGSVRYNFMNDGFFLKVTLSFTPRPDQDHTDLTCHVDSRKGVSQAQRTVRLVAYAP 180
Qy 181 RDLVTSISRDNTPALEPQGNVPLYEAQKQFLLCDAADSPATLSWLNQVLS 240
Db 181 RDLVTSISRDNTPALEPQGNVPLYEAQKQFLLCDAADSPATLSWLNQVLS 240
Qy 241 HPWGPRLGLELPVKGAGDSGRYTCRAENRLGSGQORALDLSVQYPPENLRVWVSQANRTV 300
Db 241 HPWGPRLGLELPVKGAGDSGRYTCRAENRLGSGQORALDLSVQYPPENLRVWVSQANRTV 300
Qy 301 LENLNGTSLPVLGQSLCLVCVTHSSPPARLSWTORQGVLSPPQSDPGVLELPRVQVE 360
Db 301 LENLNGTSLPVLGQSLCLVCVTHSSPPARLSWTORQGVLSPPQSDPGVLELPRVQVE 360
Qy 361 HEGEFTCHARHPLGSHVSLSVHYSPKLLGPGSCSWEAEGHLCSSQASPAFLSLANWL 420

1071	DB	CTGAGCCCTTCCAGGCCCTTCAGACCCCGGGGTCTCGAGCTGCGCTTCGAGTTCGAGTGGAG	1130
1081	QY	CAGAAAGAGAGTTTCACTCTGCCACGCTCGGCACCACTGGGCTCCGAGCACGTCTCTCTC	1140
1131	DB	CAGAAAGAGAGTTTCACTCTGCCACGCTCGGCACCACTGGGCTCCGAGCACGTCTCTCTC	1190
1141	QY	AGCTCTCTCGTGCACTACTCTCCCGAAGCTGTGGGCCCTCTCTGCTCTCTGGAGGGCTGAG	1200
1191	DB	AGCTCTCTCGTGCACTACTCTCCCGAAGCTGTGGGCCCTCTCTGCTCTCTGGAGGGCTGAG	1250
1201	QY	GGTCTGCATCTGCAGCTGTCTCTCCAGGCCAGCCCGGCCCTCTCTCTGCGCTGGTGGCTT	1260
1251	DB	GGTCTGCATCTGCAGCTGTCTCTCCAGGCCAGCCCGGCCCTCTCTGCGCTGGTGGCTT	1310
1261	QY	GGGAGGAGCTGTCTGGAGGGGAAACAGACCCAGGACTCTTTCTGAGGCTACCCCCAGCTCA	1320
1311	DB	GGGAGGAGCTGTCTGGAGGGGAAACAGACCCAGGACTCTTTCTGAGGCTACCCCCAGCTCA	1370
1321	QY	GCCGGGCCCTGGGCGCAACAGCTCTCTGAGCCTTCATGGAGGGCTCAGTCCGGCTCAGG	1380
1371	DB	GCCGGGCCCTGGGCGCAACAGCTCTCTGAGCCTTCATGGAGGGCTCAGTCCGGCTCAGG	1430
1381	QY	CTCGCTGTGAGCGCTCGAAACGTCATGCGGCCAGAGTGGATCCATCTCTGCAGCTGCCA	1440
1431	DB	CTCGCTGTGAGCGCTCGAAACGTCATGCGGCCAGAGTGGATCCATCTCTGCAGCTGCCA	1490
1441	QY	GATAAGAAAGGAGCTCATCTCTCAACGGCATTTCTCAACGGAGCGTTCTTGGGGAATCGGCATC	1500
1491	DB	GATAAGAAAGGAGCTCATCTCTCAACGGCATTTCTCAACGGAGCGTTCTTGGGGAATCGGCATC	1550
1501	QY	ACGGCTCTTTCTTTCTCTGCTCTGGCGCTGATCATCTGAAGATTCTACCGAAGACGCG	1560
1551	DB	ACGGCTCTTTCTTTCTCTGCTCTGGCGCTGATCATCTGAAGATTCTACCGAAGACGCG	1610
1561	QY	ACTCAGACAGAAACCCCGAGGCCAGGTTCTCCGGGCACAGCAGATCTCTGGATTACATC	1620
1611	DB	ACTCAGACAGAAACCCCGAGGCCAGGTTCTCCGGGCACAGCAGATCTCTGGATTACATC	1670
1621	QY	AATGTGTCTCCGAGCGCTGCGCCCTCTGCTCAGAGCGGATCAGAAGCCACACCAAC	1680
1671	DB	AATGTGTCTCCGAGCGCTGCGCCCTCTGCTCAGAGCGGATCAGAAGCCACACCAAC	1730
1681	QY	AGTCTCTCGGACCCCTCTTCCACGAGTGCTCCCTCCCAAGATCAAAAGAAAGAACCCAGAA	1740
1731	DB	AGTCTCTCGGACCCCTCTTCCACGAGTGCTCCCTCCCAAGATCAAAAGAAAGAACCCAGAA	1790
1741	QY	AAGCAGTATCAGTTGGCCAGTTTCCAGAAACCAATCATCCACTCAGGCCCCAGAGATCC	1800
1791	DB	AAGCAGTATCAGTTGGCCAGTTTCCAGAAACCAATCATCCACTCAGGCCCCAGAGATCC	1850
1801	QY	CAGAGAGCCAGAGAGAGCTCATTTATGCGACGCTCAACTTCCAGGGGCTCAGACCCAGG	1860
1851	DB	CAGAGAGCCAGAGAGAGCTCATTTATGCGACGCTCAACTTCCAGGGGCTCAGACCCAGG	1910
1861	QY	CCTGAGGCCCGGATGCCAACGGGCAACCCAGGCGGATTATGCAAGATCAAGTTCCAA	1917
1911	DB	CCTGAGGCCCGGATGCCAACGGGCAACCCAGGCGGATTATGCAAGATCAAGTTCCAA	1967

RESULT 3

AAV99911 standard; cDNA; 3099 BP.

AAV99911;

26-APR-1999 (first entry)

Human sialoadhesin family 4 (SAF-1) cDNA.

SAP-4; sialoadhesin family; human; therapy; diagnosis; cancer;
 inflammation; autoimmune disease; allergy; asthma; inflammation;
 cerebellar degeneration; Alzheimer's disease; Parkinson's disease;

KW	multiple sclerosis, amyotrophic lateral sclerosis; head injury;
KW	septic shock; sepsis; stroke; osteoporosis; osteoarthritis;
KW	ischemia reperfusion injury; cardiovascular disease; kidney disease;
KW	liver disease; myocardial infarction; hypertension; AIDS;
KW	myelodysplastic syndrome; aplastic anaemia; baldness; infection; ss.
OS	Homo sapiens.
OS	
FE	Key
FE	Location/Qualifiers
FT	51..1970
FT	/*tag= a
FT	
PN	W09853840-A1.
PN	
PD	03-DEC-1998.
PD	
PF	27-MAY-1998; 98WO-US010791.
PF	
PR	27-MAY-1997; 97US-0047572P.
PR	
XX	(SMIX) SMITHKLINE BEECHAM CORP.
XX	
XX	Kixly KK, Erickson-Miller CL;
XX	
XX	WPI; 1999-080779/07.
XX	P-PSDB; AAW81023.
XX	
XX	New sialoadhesin family 4 polypeptides and polynucleotides - useful to
PT	creat various diseases associated with SAP-4 expression.
PT	
XX	Claim 2; Page 30-31; 49pp; English.
XX	
XX	This cDNA clone codes for new human sialoadhesin family 4 (SAP-4)
CC	polypeptide (see AAW81023). It can be obtained e.g. from a cDNA library
CC	derived from mRNA in cells of human primary dendritic cells, using
CC	expressed sequence tag analysis. SAP-4 polynucleotides and polypeptides,
CC	and methods for producing such polypeptides by recombinant techniques are
CC	disclosed. SAP-4, its agonists and antagonists, and nucleic acid
CC	molecules that enhance or inhibit SAP-4 expression, may be used to treat
CC	patients in need of enhancement or inhibition of SAP-4 expression or
CC	activity. Conditions that may benefit from such treatment include cancer,
CC	inflammation, autoimmunity, allergy, asthma, rheumatoid arthritis, CNS
CC	inflammation, cerebellar degeneration, Alzheimer's disease, Parkinson's
CC	disease, multiple sclerosis, amyotrophic lateral sclerosis, head injury
CC	damage and other neurological disorders, septic shock, sepsis, stroke,
CC	osteoporosis, osteoarthritis, ischemia reperfusion injury, cardiovascular
CC	disease, kidney disease, liver disease, ischemic injury, myocardial
CC	infarction, hypotension, hypertension, AIDS, myelodysplastic syndromes
CC	and other haematologic abnormalities, aplastic anaemia, male baldness
CC	pattern and bacterial, protozoal, fungal and viral infections related to
CC	SAP-4 polypeptide activity. Methods of identifying agonists,
CC	antagonists/inhibitors are also provided, as well as diagnostic assays
CC	for detecting diseases associated with inappropriate SAP-4 activity or
CC	levels

Sequence 3099 BP; 769 A; 908 C; 813 G; 607 T; 0 U; 2 Other;

Query Match 100.0%; Score 1917; DB 2; Length 3099;

Best Local Similarity	100.0%	Pred. No. 0;
Matches 1917: Conservative	0:	Mismatches
	0:	Indels
	0:	Gaps

On 7 3 TACGTAATGCTGCTGGGCTCCAGGCTATGATGGAGGA 60

[illegible]

100

100

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	52
--	---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	----

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

DD 17T 19621111CICCCIAACCCCGAAGAC:GGAAGAGGTCIAACCCCGAAGAC1960 4230